Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Welch Group LLC cut its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 35.1% in the fourth quarter, HoldingsChannel reports ...

Pfizer Inc. (NYSE: PFE) shares are trading lower Tuesday after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.'s nomination for Secretary of Health and Human Services.

Today, Benzinga's options scanner spotted 33 options trades for Pfizer. This is not a typical pattern. The sentiment among these major traders is split, with 66% bullish and 33% bearish. Among all the ...

Highlights,Welch Group LLC reduced its position in Pfizer,(NYSE:PFE),by over 35% in the fourth quarter.,Institutional ...

US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...

Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...

Strong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.9% year on year to $17.76 billion. On the other hand, the company ...